論文

査読有り 国際誌
2020年

Evaluation of Systemic Inflammatory Response and Nutritional Biomarkers as Predictive Factors in Patients with Recurrent Gastric Cancer.

Oncology
  • Tsutomu Namikawa
  • Keiichiro Yokota
  • Sachi Yamaguchi
  • Jun Iwabu
  • Masaya Munekage
  • Sunao Uemura
  • Shigehiro Tsujii
  • Hiromichi Maeda
  • Hiroyuki Kitagawa
  • Masamitsu Kumon
  • Michiya Kobayashi
  • Kazuhiro Hanazaki
  • 全て表示

98
7
開始ページ
452
終了ページ
459
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1159/000505973

BACKGROUND: The present study sought to evaluate host-related factors as predictors in patients receiving chemotherapy for recurrent advanced gastric cancer. METHODS: Sixty-three patients were enrolled in the study and received chemotherapy for recurrent gastric cancer at the Kochi Medical School from 2008 to 2015. Clinicopathological information and systemic inflammatory response data were obtained retrospectively to investigate associations between baseline cancer-related prognostic variables and survival outcomes. RESULTS: The median survival time was significantly higher for patients with a Glasgow prognostic score (GPS) of 0 compared to a GPS of 1 or 2 (18.2 vs. 7.1 months; p = 0.006), and for patients in the normal range for carbohydrate antigen-125 (CA125) compared to higher levels (17.9 vs. 4.1 months; p = 0.003). There was no significant influence on overall survival by age, gender, disease status, metastatic site, time to recurrence, carcinoembryonic antigen level, CA19-9 level, prognostic nutrition index, or neutrophil to lymphocyte ratio according to the results of the univariate log-rank tests. Multivariate survival analysis identified a GPS of 1 or 2 (hazard ratio, 3.520; 95% confidence interval, 1.343-9.227; p = 0.010) and a high CA125 level (hazard ratio, 3.135; 95% confidence interval, 1.276-7.697; p = 0.013) as significant independent predictors associated with a poorer prognosis in the studied group of cancer patients. CONCLUSIONS: A GPS of 1 or 2 and a high level of CA125 are independent predictors of a poorer prognosis in patients receiving chemotherapy for recurrent gastric cancer.

リンク情報
DOI
https://doi.org/10.1159/000505973
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/32182616
ID情報
  • DOI : 10.1159/000505973
  • PubMed ID : 32182616

エクスポート
BibTeX RIS